BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 1599915)

  • 1. Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen-Friedenreich) determinant using a synthetic carbohydrate antigen.
    MacLean GD; Bowen-Yacyshyn MB; Samuel J; Meikle A; Stuart G; Nation J; Poppema S; Jerry M; Koganty R; Wong T
    J Immunother (1991); 1992 May; 11(4):292-305. PubMed ID: 1599915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer.
    Slovin SF; Ragupathi G; Musselli C; Fernandez C; Diani M; Verbel D; Danishefsky S; Livingston P; Scher HI
    Cancer Immunol Immunother; 2005 Jul; 54(7):694-702. PubMed ID: 15726361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune responses of mice and human breast cancer patients following immunization with synthetic sialyl-Tn conjugated to KLH plus detox adjuvant.
    Longenecker BM; Reddish M; Koganty R; MacLean GD
    Ann N Y Acad Sci; 1993 Aug; 690():276-91. PubMed ID: 7690215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specificity of the IgG response in mice and human breast cancer patients following immunization against synthetic sialyl-Tn, an epitope with possible functional significance in metastasis.
    Longenecker BM; Reddish M; Koganty R; MacLean GD
    Adv Exp Med Biol; 1994; 353():105-24. PubMed ID: 7527178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of synthetic TF-KLH (keyhole limpet hemocyanin) and sTn-KLH conjugates in colorectal carcinoma patients.
    Adluri S; Helling F; Ogata S; Zhang S; Itzkowitz SH; Lloyd KO; Livingston PO
    Cancer Immunol Immunother; 1995 Sep; 41(3):185-92. PubMed ID: 7553688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine.
    MacLean GD; Reddish MA; Koganty RR; Longenecker BM
    J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):59-68. PubMed ID: 8859725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant.
    MacLean GD; Reddish M; Koganty RR; Wong T; Gandhi S; Smolenski M; Samuel J; Nabholtz JM; Longenecker BM
    Cancer Immunol Immunother; 1993; 36(4):215-22. PubMed ID: 8439984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer.
    Miles DW; Towlson KE; Graham R; Reddish M; Longenecker BM; Taylor-Papadimitriou J; Rubens RD
    Br J Cancer; 1996 Oct; 74(8):1292-6. PubMed ID: 8883420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of terminal residue on adjacent disaccharide immunogenicity.
    Irazoqui FJ; Lopez PH; Mandel U; Nores GA
    Mol Immunol; 2002 Mar; 38(11):825-31. PubMed ID: 11922940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Constructing an adenocarcinoma vaccine: immunization of mice with synthetic KH-1 nonasaccharide stimulates anti-KH-1 and anti-Le(y) antibodies.
    Ragupathi G; Deshpande PP; Coltart DM; Kim HM; Williams LJ; Danishefsky SJ; Livingston PO
    Int J Cancer; 2002 May; 99(2):207-12. PubMed ID: 11979435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal antibodies and synthetic tumor-associated glycoconjugates in the study of the expression of Thomsen-Friedenreich-like and Tn-like antigens on human cancers.
    Longenecker BM; Willans DJ; MacLean GD; Selvaraj S; Suresh MR; Noujaim AA
    J Natl Cancer Inst; 1987 Mar; 78(3):489-96. PubMed ID: 3469463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancers.
    Ragupathi G; Koide F; Sathyan N; Kagan E; Spassova M; Bornmann W; Gregor P; Reis CA; Clausen H; Danishefsky SJ; Livingston PO
    Cancer Immunol Immunother; 2003 Oct; 52(10):608-16. PubMed ID: 12811527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine.
    Sandmaier BM; Oparin DV; Holmberg LA; Reddish MA; MacLean GD; Longenecker BM
    J Immunother; 1999 Jan; 22(1):54-66. PubMed ID: 9924700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines.
    Kim SK; Ragupathi G; Musselli C; Choi SJ; Park YS; Livingston PO
    Vaccine; 1999 Nov; 18(7-8):597-603. PubMed ID: 10547417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IgG immune response to tumor-associated carbohydrate antigens (TF, Tn, alphaGal) in patients with breast cancer: impact of neoadjuvant chemotherapy and relation to the survival.
    Kurtenkov O; Klaamas K; Rittenhouse-Olson K; Vahter L; Sergejev B; Miljukhina L; Shljapnikova L
    Exp Oncol; 2005 Jun; 27(2):136-40. PubMed ID: 15995632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct demonstration of increased expression of Thomsen-Friedenreich (TF) antigen in colonic adenocarcinoma and ulcerative colitis mucin and its concealment in normal mucin.
    Campbell BJ; Finnie IA; Hounsell EF; Rhodes JM
    J Clin Invest; 1995 Feb; 95(2):571-6. PubMed ID: 7860740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of antibody titers after immunization with monovalent or tetravalent KLH conjugate vaccines.
    Ragupathi G; Cappello S; Yi SS; Canter D; Spassova M; Bornmann WG; Danishefsky SJ; Livingston PO
    Vaccine; 2002 Jan; 20(7-8):1030-8. PubMed ID: 11803062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific immunosuppressive activity of epiglycanin, a mucin-like glycoprotein secreted by a murine mammary adenocarcinoma (TA3-HA).
    Fung PY; Longenecker BM
    Cancer Res; 1991 Feb; 51(4):1170-6. PubMed ID: 1825477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of human tumor associated Thomsen-Friedenreich antigen.
    Samuel J; Noujaim AA; MacLean GD; Suresh MR; Longenecker BM
    Cancer Res; 1990 Aug; 50(15):4801-8. PubMed ID: 2196117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunization with N-propionyl polysialic acid-KLH conjugate in patients with small cell lung cancer is safe and induces IgM antibodies reactive with SCLC cells and bactericidal against group B meningococci.
    Krug LM; Ragupathi G; Hood C; George C; Hong F; Shen R; Abrey L; Jennings HJ; Kris MG; Livingston PO
    Cancer Immunol Immunother; 2012 Jan; 61(1):9-18. PubMed ID: 21811785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.